Logo image
Back
Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine
Journal article   Peer reviewed

Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine

Joseph A. Bocchini, Robert S. Baltimore, Henry H. Bernstein, John S. Bradley, Michael T. Brady, Penelope H. Dennehy, Margaret C. Fisher, Robert W. Frenck, David W. Kimberlin, Sarah S. Long, …
Pediatrics (Evanston), v 119(1), pp 171-181
01 Jan 2007
DOI: https://doi.org/10.1542/peds.2006.3134
PMID: 17200286
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Life Sciences & Biomedicine Pediatrics Science & Technology
On February 3, 2006, a bovine-based pentavalent rotavirus vaccine (RotaTeq, Merck & Co Inc, Whitehouse Station, NJ) was licensed by the US Food and Drug Administration for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants with 3 doses of pentavalent rotavirus vaccine administered orally at 2, 4, and 6 months of age. The first dose should be administered between 6 and 12 weeks of age; immunization should not be initiated for infants older than 12 weeks of age. Subsequent doses should be administered at 4- to 10-week intervals, and all 3 doses of vaccine should be administered by 32 weeks of age. Pentavalent rotavirus vaccine can be coadministered with other childhood vaccines. Pentavalent rotavirus vaccine is contraindicated for infants with a serious allergic reaction to any vaccine component or to a previous dose of vaccine.

Metrics

3 Record Views
54 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Pediatrics
Logo image